logo

News

    • 01 APR 2021

    PharmaCyte Biotech Successfully Completes 1 Year Stability Study

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial

    Read more →
    • 26 JAN 2021

    PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product

    LAGUNA HILLS, CA, January 26, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional studies to determine the exact sequence of the DNA encoding of the enzyme in the cells of its CypCaps® product for pancreatic

    Read more →
    • 14 DEC 2020

    PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product

    LAGUNA HILLS, CA, December 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional physical parameter testing of its CypCaps® product for pancreatic cancer, in line with the recommendations

    Read more →
    • 02 DEC 2020

    PharmaCyte Biotech Successfully Completes 9-Month Stability Study

    LAGUNA HILLS, CA, December 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration

    Read more →
    • 04 NOV 2020

    PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND).

    Read more →
    • 02 OCT 2020

    PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA

    LAGUNA HILLS, CA, October 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the company’s submitted Investigational New Drug

    Read more →
    • 23 SEP 2020

    PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

    LAGUNA HILLS, CA, September 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it continues to engage with the U.S. Food and Drug Administration (FDA) during its 30-day comment period regarding

    Read more →
    • 14 SEP 2020

    PharmaCyte Biotech Successfully Completes Six-Month Stability Study

    LAGUNA HILLS, CA, September 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the six-month product stability testing that is required by the U.S. Food and Drug

    Read more →
    • 08 SEP 2020

    PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test

    LAGUNA HILLS, CA, September 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the second Container Closure Integrity (CCI) test that is required by the U.S. Food

    Read more →
    • 02 SEP 2020

    PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

    LAGUNA HILLS, CA, September 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for

    Read more →

Subscribe to Our Mailing List

* indicates required
Email Format